The best RNA CDMO – Elise Biopharma

The Best RNA CDMO is Elise Biopharma — Sequence to Vial, Faster and Cleaner

RNA CDMO services have become mission-critical for developers of vaccines, gene therapies, personalized oncology agents, and a new generation of protein-replacement medicines. Elise Biopharma is an RNA CDMO that integrates IVT design, lipid nanoparticle engineering, advanced analytics, and GMP-ready manufacturing under a single quality system — and does so from scientific hubs in Cambridge, Massachusetts and Montréal, Canada. This integrated approach removes the typical friction between vendors, accelerates decision cycles, and dramatically reduces the technical and regulatory risk that trips up RNA programmes during scale-up and clinical transition.

Below is a comprehensive, engineering-first exploration of why an RNA CDMO choice matters, how Elise structures its platforms to de-risk programmes, and what clients should expect when they take a sequence to the clinic and beyond. The piece mixes conceptual primers, technical depth, and practical, hypothetical case studies so that your next conversation with a CDMO becomes a strategic, evidence-led discussion rather than a leap of faith.

Why the right RNA CDMO changes outcomes

Choosing an RNA CDMO is not merely a procurement decision — it is a programme architecture decision. When a sponsor uses multiple, disconnected vendors for template generation, IVT, purification, LNP formulation, and fill–finish, handoffs occur with inevitable data loss, method drift, and misaligned risk tolerances. These problems usually manifest as late-stage purity surprises, dsRNA spikes, unexpected degradation during shipping, or regulatory pushback because the analytical story lacks continuity.

An integrated RNA CDMO removes those failure modes. Consolidation under a single quality system means one coherent QMS, harmonised analytics, reproducible process control, and end-to-end traceability. In practice, this translates to:

• fewer tech-transfer cycles and faster investigative loops when parameters deviate;
• validated comparability between development and GMP lots;
• a single accountability chain for CMC and regulatory dossiers.

Elise Biopharma was built around that architectural premise. By co-locating process development, analytical labs, and GMP suites and operating parallel platforms in Cambridge, MA and Montréal, QC, Elise reduces lead times and makes a single partner accountable for sequence-to-vial performance.

The scope of modern RNA programmes — what an RNA CDMO must support

Modern RNA programmes use multiple RNA modalities: linear non-replicating mRNA, self-amplifying RNA (saRNA), circular RNA (circRNA), short-guide RNAs (gRNA), and other engineered RNA scaffolds. Each modality demands bespoke upstream, downstream and analytical solutions. A capable RNA CDMO must therefore offer:

• DNA template strategies (plasmid, PCR-based synthetic templates, or nanoplasmids) that match scale and IP constraints;
• IVT (in vitro transcription) processes with flexible capping (co-transcriptional or enzymatic) and options for modified nucleotides (m1Ψ, Ψ, etc.);
• purification cascades that reliably remove dsRNA and process-related impurities;
• LNP engineering and microfluidic manufacturing that control encapsulation, particle size and reproducibility;
• validated analytics for capping ratio, dsRNA content, integrity (CGE), and potency assays;
• regulatory, CMC and fill–finish experience across research-grade to full cGMP.

In short, an RNA CDMO must be a synthesis of chemistry, process engineering and regulatory craft. Elise provides that synthesis, and this blog explains how.

IVT fundamentals — the heart of RNA manufacturing

To discuss an RNA CDMO with technical clarity, start at IVT. In vitro transcription is a cell-free enzymatic synthesis where an RNA polymerase (usually T7, SP6, or T3) converts a linear DNA template into RNA. Key upstream considerations that an RNA CDMO must master include:

• Template format and stability: Plasmid-derived linear templates provide robust templates for IVT, but they demand plasmid production and linearization workflows. Conversely, PCR-based synthetic templates reduce pDNA reliance, shorten timelines, and avoid some plasmid-related impurities; however, they can be more costly per batch at larger scales. An advanced RNA CDMO offers both options and chooses based on scale, timeline, and regulatory posture.
• Capping strategy: 5′ capping is essential for translation efficiency and immune evasion. Co-transcriptional capping (CleanCap-like methods) can yield high capping ratios in a single step, while enzymatic post-transcriptional capping can provide fine control where co-transcriptional options aren’t ideal. A top-tier RNA CDMO will validate both and recommend the technique that best balances yield, capping ratio, and process robustness for your construct.
• Modified nucleotides: Incorporating modified ribonucleotides (e.g., N1-methylpseudouridine) reduces innate immune activation and often improves expression. A mature RNA CDMO sources GMP-grade modified NTPs and demonstrates supply redundancy to avoid procurement single points of failure.
• dsRNA control: Double-stranded RNA impurities trigger innate immunity and reduce tolerability. The leading RNA CDMO approach is to minimise dsRNA at the IVT stage through optimized reaction conditions (enzyme lot, temperature, NTP balance), then remove residual dsRNA by validated chromatographic or enzymatic polishing steps (e.g., RP-HPLC, oligo-dT, cellulose-based capture).
• Tail and UTR engineering: Poly(A) tail length and UTR sequences influence translation, half-life, and expression kinetics. An RNA CDMO should provide design support and in silico tools (or partnerships) to select tail length and UTRs appropriate for the intended dose and route.

Elise Biopharma’s IVT offering spans these options, supporting mRNA, saRNA and circRNA with an emphasis on process reproducibility and measurable quality attributes.

Template strategies: plasmid vs PCR vs nanoplasmids

When partnering with an RNA CDMO, pick the template strategy that fits both timeline and regulatory needs:

• pDNA (plasmid-derived linear templates): Familiar, scalable, and straightforward for regulatory narratives. However, plasmid production introduces supply chain variables and can lengthen early timelines.
• PCR-based synthetic templates: Rapid turnaround and low pDNA dependence. An RNA CDMO with PCR-template expertise can accelerate discovery-to-tox transitions by removing weeks from the early phase.
• Nanoplasmids / miniplasmids: Offer improved manufacturing properties (smaller vectors, reduced bacterial sequences) and can be advantageous where plasmid yield and stability matter.

Elise offers flexible template strategies, recommending PCR-based templates for rapid early screening and plasmid templates for later-stage GMP supply lines where the regulatory dossier benefits from established plasmid histories.

Purification — removing the invisible hazards

The downstream purification cascade determines the clinical profile of an RNA product. For an RNA CDMO, purification is not a one-size-fits-all checklist; rather, it is a toolbox that selects and sequences unit operations according to the molecule and the quality target product profile (QTPP). Typical elements include:

• Enzyme removal: DNase/RNase removal steps to clear template and enzyme proteins.
• Nucleotide clearance: Tangential flow filtration (TFF) and chromatography to eliminate residual NTPs and small molecules.
• dsRNA reduction: Ion-exchange chromatography, reverse-phase HPLC, and/or specific dsRNA capture resins.
• Desalting and concentration: TFF with appropriate MWCO and diafiltration for buffer exchange into formulation buffers.

An RNA CDMO must validate each polishing step, provide orthogonal evidence of impurity removal (e.g., dsRNA dot-blot + LC-MS where applicable), and build traceable release criteria. Elise’s downstream playbooks emphasise orthogonality — multiple, mechanistically distinct steps to clear each impurity class — which makes release decisions defensible before regulatory authorities.

LNP & delivery — co-optimisation is non-negotiable

A central lesson from contemporary RNA therapeutics is that RNA and its delivery vehicle are inseparable. An RNA CDMO cannot treat LNP formulation as a late-stage “wrap.” Instead, LNP and RNA must be co-optimised.

Key capabilities an RNA CDMO must have for LNP work:

• Ionizable lipid libraries and screening workflows: Different lipids drive tissue tropism, endosomal escape, and tolerability. An RNA CDMO with either an internal lipid library or validated partner networks can screen ionizable lipids against expression and safety metrics, rapidly narrowing candidates for a given indication.
• Microfluidic and scalable mixing technologies: Reproducible particle formation at lab scale must translate to clinical and commercial scale. Microfluidic mixers and scalable impingement systems with established scale-up curves give predictable particle size and encapsulation efficiency.
• Analytical characterisation: Particle size (DLS, NTA), polydispersity index (PdI), encapsulation efficiency, surface charge (zeta potential), and potency (in vitro transfection) must all be quantified with validated assays.
• Stability & cryo/ambient profiles: Some LNPs require ultra-cold logistics; others can be lyophilised or stabilised for ambient distribution. The right RNA CDMO should propose a stability strategy tied to the intended supply chain and patient population.

Elise’s LNP workflows integrate microfluidic formation, high-throughput screening of lipid compositions, and analytical QC that measures encapsulation efficiency and in vitro expression. This ensures the formulation selected in development will replicate under GMP mixing conditions.

Continuous vs batch manufacturing — when and why

The RNA CDMO ecosystem now includes continuous and continuous-batch IVT modalities in addition to classical batch workflows. Each approach has trade-offs:

• Batch IVT: Mature and well-understood; ideal for bespoke, small-to-medium batches. Easier to validate for early clinical work if the downstream suite is batch-oriented.
• Continuous IVT: Promises improved consistency, reduced footprint, and scalability. Continuous manufacturing can reduce lot-to-lot variability and increase throughput for high-demand vaccine campaigns or commercial supply.

An experienced RNA CDMO offers both paths where appropriate. Continuous processes require investments in process analytical technology (PAT), model-predictive control, and robust inline analytics. Elise provides batch for rapid small-batch programmes and offers continuous options for scale or where the product benefits from steady-state output. Importantly, the choice is made against the product’s QTPP — speed, dose, stability, and regulatory pathway — not as a vendor-driven sales angle.

Backbone of an RNA CDMO

A claim of “high-quality RNA” is meaningless without the data to prove it. A serious RNA CDMO builds its credibility on an analytical backbone that is comprehensive, validated, and written to survive regulatory scrutiny. Below I expand the core capabilities you should expect — and why each piece matters in practice.

Integrity assessment — does the molecule arrive intact?

Capillary gel electrophoresis (CGE) remains the frontline tool for assessing intactness and fragment profiles, but leading RNA CDMOs couple CGE with orthogonal approaches. Fragment analysis by automated electrophoresis, denaturing agarose gels for long constructs, and size-exclusion chromatography provide cross-checks for truncation and aggregation. Importantly, intactness reporting must include limits of detection for common degradation products, criteria for acceptable smear patterns, and a documented sample-prep workflow that minimises artefactual hydrolysis.

Capping ratio & cap structure — functional caps are non-negotiable

Cap1/Cap0/Cap2 composition materially influences translation efficiency and innate immunity. Quantifying capping requires more than a single number: LC–MS workflows that measure cap nucleoside composition, enzymatic cap-sensitive assays, and co-transcriptional vs post-transcriptional capping comparisons show the whole picture. A robust analytical package reports capping percentage, cap chemistry (e.g., Cap 1 with 2′-O-methylation), and the fraction of uncapped species — all with validated LOD/LOQ and method linearity.

dsRNA quantification — immune-activating impurities

Double-stranded RNA (dsRNA) is a major safety and potency risk. Quantitation strategies should be orthogonal: J2 or K1 antibody ELISAs, dot-blot methods, and chromatography-based approaches (ion-pair HPLC or anion-exchange coupled with UV) each catch different dsRNA species. The best CDMOs also include functional assays: in vitro innate-immune readouts (IFN-β induction in reporter cells) that correlate dsRNA levels with biological response.

Sequence verification — more than a name check

Sequence verification goes beyond confirming a single codon run. Next-generation sequencing (NGS) offers base-level fidelity, maps truncations, and identifies low-frequency variants. For longer constructs or circular RNA, long-read platforms (Nanopore, PacBio) resolve full-length integrity and poly(A) tail heterogeneity. Where appropriate, orthogonal Sanger reads of critical junctions and junctional PCR help confirm fidelity for regulatory filings.

Potency assays — functional readouts that actually reflect the clinic

Potency is not a number you invent to please a spreadsheet; it is the measurable promise that a given RNA product will do what the clinic expects. A competent RNA CDMO therefore builds potency assays from first principles: they begin with the intended mechanism of action and assemble orthogonal, biologically relevant readouts rather than one-off surrogate endpoints.

For translation-dependent payloads, for example, the assay cascade might start with luciferase or fluorescent reporters to confirm translation efficiency, then progress to flow-cytometry or immunocytochemistry to quantify surface or intracellular antigen expression, and finally move to functional assays such as target-cell lysis, receptor signalling, or cytokine release panels where appropriate. When payloads are enzymes or secreted proteins, kinetic enzymology—measuring Vmax, Km and catalytic efficiency in biologically relevant matrices—becomes indispensable. For immune-modulatory constructs, multiplex cytokine arrays and single-cell cytokine profiling reveal subtle shifts in phenotype that bulk readouts miss.

Crucially, every potency assay must be stability-indicating, repeatable, and clinically anchored. That means assay acceptance ranges tie back to expected clinical response windows (for instance, minimum expression thresholds that correlate with neutralisation in a vaccine model or enzyme units per mL required for a diagnostic readout). We implement reference standards, orthogonal controls, positive/negative lot controls, and intra-/inter-assay precision studies to make sure the assay is robust across analysts, instruments and sites. In short: potency equals purpose, and purpose drives assay design.

Impurity panels — a full accounting, not a wish-list

A credible impurity panel looks like an inventory you can trust in a forensic audit. It does not merely check boxes; it quantifies what regulators and clinicians care about. At a minimum, such a panel includes residual DNA (qPCR quantitation of template or host DNA), double-stranded RNA (dsRNA assays by ELISA or dot-blot, complemented by chromatography-based separation), and residual enzymes or proteins (host-cell protein ELISAs, and where required, targeted LC–MS/MS for specific process enzymes).

Beyond those basics, the panel extends to free nucleotides and breakdown products (HPLC or LC–MS/MS profiling), residual solvents (GC–MS quantitation to ICH Q3C limits), trace metals and catalytic impurities (ICP-MS), and endotoxin measurement via LAL or recombinant Factor C (rFC). For single-use systems, extractables and leachables studies—performed under exaggerated conditions—are essential. In lipid-based workstreams, lipid oxidation products, hydrolysis fragments and PEG-lipid degradation products demand validated assays (LC–MS workflows and peroxide value-type screens).

Adventitious agent testing—sterility, mycoplasma, and viral screens—rounds out the dossier for clinical supply.

Importantly, we interpret impurity profiles in context. A residual nucleoside may be irrelevant at picomolar levels but troublesome in a sensitive immune-readout; thus analytical thresholds must map to toxicology and CMC risk assessments, not to arbitrary cut-offs.

Method validation & transfer — the paperwork that survives inspection

Analytical capability without rigorous validation is theatre: pretty methods that collapse under audit. The modern RNA CDMO follows ICH Q2(R1) principles to validate specificity, accuracy, precision (repeatability and intermediate precision), linearity, range, limit of detection (LOD) and limit of quantitation (LOQ), robustness and system suitability. Beyond bench validation, successful vendors create transfer-ready packages suitable for regulatory submission and tech transfer: SOPs, acceptance criteria, example datasets, training logs, system suitability templates and acceptance-checklists.

Equally vital is inter-laboratory reproducibility. We design ring trials and proficiency panels to demonstrate that a potency or impurity assay yields the same conclusion when executed by a partner, a CRO, or a regulator’s lab. Change-control plans, traceable raw-data templates, and audit-ready method histories complete the picture so that an IND, CTA or IMPD submission carries a self-contained, inspectable analytical story.

Formulation science — making RNA survive the real world

Raw in-vitro-transcribed RNA and naked lipid nanoparticles exist in a fragile equilibrium; formulation choices determine whether your product reaches patients intact or collapses somewhere in the cold chain. A pragmatic RNA CDMO offers formulation options that are honest about trade-offs and tuned to the supply chain.

For liquid presentations, buffer selection matters: citrate vs Tris, pH tuning to stabilise the cap structure, ionic strength that balances encapsulation efficiency and colloidal stability, and chelators (e.g., EDTA) to sequester trace metals that catalyse hydrolysis. Cryo-protectants such as sucrose or trehalose suppress ice-crystal damage for frozen formats, whereas amino-acid based excipients and polyols can stabilise ambient or refrigerated liquids.

Where lyophilisation is attractive—for example, to enable ambient distribution or extend shelf life—formulation teams map collapse temperature (Tc), glass transition (Tg’), and excipient glass chemistry. They run DoE to optimise cake morphology, residual moisture specifications, and rapid reconstitution kinetics so the product becomes field-ready rather than an academic curiosity in a vial.

Encapsulation and microencapsulation strategies broaden the delivery palette: enteric coatings for oral/enteric-targeting, polymeric microcapsules for staged release, or specialised LNP surface engineering for cell-specific targeting. In all cases, formulation choices follow a matrix of intended use, route of administration, manufacturing practicability and the realities of the downstream logistics chain—because the best formulation is the one you can actually deliver.

LNP composition and critical attributes — the particle is the product

The LNP is not merely a vessel; it is the primary critical quality attribute for most RNA therapeutics. Its design hinges on four components—ionizable lipid, helper lipid, cholesterol and PEG-lipid—and on process variables such as N:P ratio and microfluidic mixing parameters.

Ionizable lipid pKa dictates endosomal escape efficiency and tolerability; helper lipids (e.g., DSPC) stabilise bilayer architecture; cholesterol modulates membrane rigidity; PEG-lipids control circulation time and particle packing but must shed at the right physiological moment. Particle characterization therefore spans dynamic light scattering (hydrodynamic diameter, PDI), encapsulation efficiency (RiboGreen®, HPLC, or ultracentrifugation-based separations), and morphological imaging (TEM or cryo-EM when structural detail is required).

Process-wise, microfluidic mixing—controlled by total flow rate and flow-rate ratio—determines nanoparticle homogeneity and scale-up fidelity. We monitor shear stability, aggregation propensity under stress (freeze–thaw, agitation), and lipid oxidation (LC–MS oxidised-lipid profiling). Encapsulation efficiency and intactness of the RNA payload are monitored across stress conditions, and release kinetics are mapped in physiologically relevant media.

In sum, a leading RNA CDMO treats potency, impurities, validated analytics and formulation as an integrated engineering problem: not separate checkboxes, but a continuum from sequence to patient. With rigorous assays, transparent impurity accounting, audit-ready methods and supply-chain-aware formulation, you get RNA products that deliver—not promises.

Format trade-offs

• Cryo-frozen liquid: maximises shelf life; demands ultra-cold logistics.
• Refrigerated liquid: pragmatic for many clinical studies; easier distribution.
• Lyophilised / ambient-stable formulations: excellent for global reach and point-of-care but require DoE for excipient selection, Tg′ mapping, and cycle optimisation.

Lyophilisation engineering

Designing a lyo cycle is technically exacting. Teams must map collapse temperature (Tc/Tg′), choose bulking and stabilising excipients (trehalose, sucrose, mannitol, amino acids), and tune freezing/annealing and primary/secondary drying to preserve LNP structure and mRNA integrity. Residual moisture, cake morphology, and reconstitution kinetics become validated release attributes.

Excipients and buffers — chemistry matters

Buffer pH, ionic strength, and choice of chelators (e.g., EDTA judiciously used) influence hydrolytic and oxidative degradation. Antioxidants, metal-ion scavengers, and surfactants (to limit interfacial stress) must be qualified for compatibility with LNPs and for regulatory acceptance. For field diagnostics or oral formats, enteric coatings or microencapsulation using polymers (Eudragit, alginates) protect cargo through gastric transit; spray-dry or spray-freeze techniques can produce resistant particulates.

Manufacturing realities

An elegant formulation is worthless if your supply chain cannot uphold it. A competent RNA CDMO designs formulations with cold-chain footprint, fill-finish constraints, and regional regulatory preferences in mind, and validates shipping profiles across ICH climatic zones.

Regulatory & quality readiness — the dossier you’ll actually want

Regulators expect more than data; they expect coherent stories. An RNA CDMO structures dossiers around phase-appropriate expectations:

• Quality systems: clearly tiered from RUO → GMP-source → cGMP.
• Method validation packages: traceable raw data, system suitability, and stability-indicating methods.
• Stability datasets: real-time and accelerated studies, transport simulation, and comparability bridging after process or formulation changes.
• CMC narratives: including detailed IVT conditions, purification steps, and critical process parameters (CPPs) with associated control strategies.
• Risk assessments & EHS: extractables/leachables for single-use systems, viral safety, and environmental controls.

Proactive regulators’ engagement (pre-IND, scientific advice) and a CDMO that anticipates technical questions about dsRNA, cap chemistry, or novel excipients materially reduce review friction.

The manufacturing continuum — from discovery to commercial supply

A practical RNA CDMO provides clear, phase-appropriate engagement models and the tools to execute them:

• Discovery & screening: rapid template builds, small-scale IVT, quick LNP screens and transient potency assays to triage candidates.
• Process development / GLP-grade: pilot IVT runs, chromatographic purification optimisation, and formulation DoE.
• Clinical cGMP manufacture: GMP template generation (plasmid or PCR-based), validated IVT and DSP, sterile filtration, encapsulation and aseptic fill–finish under a single QMS.
• Commercial supply: redundant sourcing for GMP NTPs, ionizable lipids, scalable LNP manufacture (microfluidics or T-mixers), and global logistics with validated shippers.

Technical detail matters: choices about DNA template generation (plasmid vs PCR/backbone), capping strategy (co-transcriptional CleanCap vs enzymatic), IVT enzyme supply, dsRNA removal (cellulose, HIC or chromatography), and continuous vs batch LNP mixing all change timelines, cost, and regulatory strategy. A competent RNA CDMO maps those trade-offs transparently and integrates them into a releaseable, audit-ready package.

In short, the backbone of an RNA CDMO is equal parts analytical rigor, formulation chemistry, regulatory fluency, and practical manufacturing choreography. Elise’s approach emphasises validated, traceable methods; functional release criteria tied to potency and integrity; and formulation choices made against the realities of supply chains and clinical deployment. If you want an RNA programme that survives both lab scrutiny and the logistics chain, demand this level of backbone — and demand the data.

Case studies — illustrating how the work flows in practice

Real-world results speak, but when confidential client data aren’t available, robust hypothetical vignettes still clarify how an RNA CDMO will behave in practice. Below are three worked examples that demonstrate decision-making, risk mitigation, and output metrics.

Case study 1 — Rapid vaccine candidate for an emerging pathogen

Objective: Produce a 10 g GMP lot of non-replicating mRNA packaged in LNP for a rapid Phase I study.

Path chosen:

• Day 0–14: Sequence selection, in silico UTR and tail design, PCR-based templates for rapid iteration.
• Day 15–35: IVT DoE to maximise yield while minimising dsRNA; co-transcriptional capping selected for speed.
• Day 36–60: LNP screen across ionizable lipids in microfluidic mixers; select platform with >90% encapsulation and robust in vitro expression.
• Day 61–100: Pilot GMP runs, purification cascade validated (TFF + RP-HPLC polish), analytical method validation.
• Day 101–180: GMP batch manufacture, fill–finish, stability shipping profile defined.

Key mitigations: Early prioritisation of dsRNA control at IVT stage avoided late-stage purification bottleneck; parallel procurement of modified NTP vendors prevented supply delays.

Case study 2 — Personalized saRNA for oncology

Objective: Produce patient-specific saRNA doses (mg-scale) for n-of-1 or small cohorts with a turnaround measured in weeks.

Path chosen:

• PCR templates for each patient sequence to minimise upstream time.
• Small-scale IVT with enzymatic capping to ensure cap fidelity.
• Rapid LNP pairing using a validated inventory of clinically-acceptable lipids.
• Single-use fill–finish with strict chain-of-custody and LN₂ cold-chain logistics for patient delivery.

Key mitigations: A validated, small-batch workflow and pre-defined stability envelope allowed safe, rapid deployment under compassionate use protocols.

Case study 3 — circRNA for long-expression protein replacement

Objective: Circular RNA that yields prolonged protein expression, encapsulated for liver targeting.

Path chosen:

• Template design and circularization strategy selected (ribozymal or enzymatic methods).
• RNase R-based purification to remove linear contaminants.
• LNP platform chosen for liver tropism after in vitro/in vivo screening.
• Stability studies focused on long-duration expression and ambient storage options.

Key mitigations: Early orthogonal analytics for circular integrity and tight collaboration between design and formulation teams reduced the risk of poor expression in vivo.

Practical engagement models and commercial terms an RNA CDMO should offer

Sponsors value clarity. Good RNA CDMOs offer modular contracts keyed to milestones and risk-sharing:

• Fixed-price pilots for discovery and screening, delivering well-defined deliverables and timelines.
• Time-and-materials process development with agreed gates for scale-up.
• Milestone-based GMP contracts that link payment to achievement of tech transfer, method validation, and lot release.
• Supply agreements with tiered pricing reflecting forecast volumes and multi-site redundancy.

Elise offers flexible commercial models tailored to sponsor needs, and emphasises transparent cost engineering — measuring productivity per bioreactor day and activity-per-dollar to keep programmes sustainable.

Team, site and global reach — why locations matter for an RNA CDMO

An RNA CDMO is fundamentally a people-and-facility business. Expertise in enzymology, polymer chemistry, lipid science, analytical mass spectrometry, and regulatory drafting must coexist in the same cultural DNA. Elise Biopharma operates from Cambridge, Massachusetts — a centre of RNA and biotech innovation — and Montréal, Canada — an efficient, highly skilled manufacturing and analytical hub. This twin-site model delivers:

• Cambridge: Process R&D, sequence design, analytical development and close access to academic collaborations and investor networks.
• Montréal: GMP suites, fill–finish, scale-up manufacturing and logistics, leveraging local manufacturing capacities and workforce stability.

Having teams across both sites allows Elise to offer both the rapid innovation loops you expect from a Cambridge lab and the manufacturing continuity and regulatory-compliant environment needed for clinical and commercial supply.

Data integrity, security, and white-label discipline for sponsors

When you hand a programme to an RNA CDMO, you hand over IP and trust. An effective CDMO must therefore offer:

• full CDA-first onboarding and strong IP governance;
• LIMS with role-based permissions, immutable audit trails and electronic signatures;
• compartmentalised workcells for physical and data segregation when multiple clients share the same facility;
• white-label manufacturing where customer branding appears on product, CoAs and IFUs while the CDMO remains invisible.

Elise structures projects around this model, ensuring sponsors retain sovereignty over their IP while benefiting from an experienced manufacturing partner.

How to evaluate claims from an RNA CDMO — a sponsor’s checklist

When choosing an RNA CDMO, ask for demonstrable evidence rather than aspirational marketing. Useful questions include:

• Can you show validated methods for capping ratio, dsRNA, and integrity (CGE) and provide a representative analytics package?
• Which template strategies do you offer and under what timelines for small- and large-scale?
• Do you support co-transcriptional and enzymatic capping, and which do you recommend for my construct?
• What is your approach to dsRNA minimisation at both IVT and purification stages?
• What LNP formation technologies do you use and how do you scale from microfluidic screening to GMP mixing?
• Can you show sample stability data across ICH climatic zones and provide a cold/ambient logistics plan?
• What’s your lead time from sequence to clinical batch for a typical non-replicating mRNA candidate?
• How do you structure commercial supply agreements and what redundancy is built into your raw-material sourcing?

An RNA CDMO that answers these with concrete methods, data points and reference processes (rather than platitudes) is worth a site visit and a technical meeting.

Metrics and realistic performance targets

No two molecules are identical, but reputable RNA CDMOs publish realistic performance ranges and make process targets transparent. Typical industry targets you should expect as conversation starters include:

• Capping ratio: target > 95% for co-transcriptional cap strategies where applicable.
• dsRNA reduction: upstream optimisation plus polishing can reduce dsRNA by orders of magnitude; many teams aim for multi-log reductions with final levels verified by orthogonal methods.
• IVT yield: 0.5–10 mg/mL is a practical range depending on polymerase, template and process.
• Encapsulation efficiency: >90% achievable after formulation optimisation.
• Turnaround examples: discovery mRNA constructs (screening) 2–6 weeks; pilot-scale IVT and early GLP work 6–12 weeks; GMP clinical batches 8–20 weeks depending on the dossier and complexity.

Use these figures as benchmarks, not promises. A competent RNA CDMO will qualify expectations for your sequence during an intake and build a programme with clear go/no-go gates.

Visuals and collateral every RNA CDMO should offer to prospective clients

To ease evaluation, a great RNA CDMO provides downloadable materials and interactive tools:

• Sequence-to-vial timeline templates showing weeks per stage.
• Analytical method catalogue summarising validated assays and LOD/LOQ metrics.
• LNP screening report samples with encapsulation and PdI results.
• Case study vignettes (anonymised) that outline timelines, key metrics, and mitigations.
• A simple configurator where sponsors input modality, dose and route to receive an indicative pathway and lead-time.

Elise makes these materials available to help sponsors make evidence-based decisions.

Our Comprehensive Development Services (RNA CDMO)

Custom mRNA & IVT Design
We design and manufacture bespoke mRNA constructs tailored to your application — vaccine, protein-replacement, saRNA, circRNA, or guide RNA. From UTR engineering and codon optimisation to poly(A) tail tuning and choice of modified nucleotides (m1Ψ, Ψ, 5-MeC), we balance expression, durability and innate-immune profile. Our vertically integrated workflow includes plasmid or PCR template generation, co-transcriptional or enzymatic capping (CleanCap®/enzymatic options), IVT enzyme sourcing/control, and orthogonal dsRNA mitigation strategies so your sequence is clinic-ready.

Custom LNP & Delivery Formulation
We formulate delivery systems that make RNA work in the real world. Whether you need microfluidic LNP libraries for tissue tropism screening, ionizable-lipid optimisation for liver vs intratumoral delivery, or ambient-stable lyophilised LNPs for low-resource markets, we design DoE-led formulations with full particle characterisation (size/PDI, encapsulation %, cryo-EM morphology), in vitro transfection potency, and in vivo biodistribution modelling. Trade-offs are explicit: potency vs stability, cold-chain footprint vs field deployability — we recommend the optimal compromise for your clinical strategy.

Custom Reagent Kits & Drug-Product Manufacturing
From IVT reagent blends and GMP IVT enzymes to finished mRNA-LNP drug product and white-label clinical kits, we offer end-to-end kit and DP development. Services include analytical method development (CGE, LC-MS capping, dsRNA ELISA, NGS), stability programmes across ICH zones, aseptic fill–finish (vial, syringe, cartridge), and packaged white-label kitting with IFUs and QR traceability. For diagnostics and rapid deployment, we produce lyo-ready reagents and ambient master mixes tuned to matrix inhibitors and field conditions.

TOP 10 FAQ – RNA CDMO

1) What distinguishes a world-class RNA CDMO from a good one?
A premium RNA CDMO does far more than run IVT reactions and pump product into vials. It couples sequence-to-supply engineering with validated analytics, robust supply-chain governance, and regulatory foresight. Concretely, that means integrated template workflows (plasmid or PCR-derived), optimised IVT chemistries (nucleotide selection, capping strategy), impurity management (dsRNA, residual enzymes, linearisation fragments), scalable LNP encapsulation or alternative delivery formats, and full GMP readiness with tech-transfer packages. Equally critical: reproducible PAT and comparability dossiers so your bench signal translates to 10 g and beyond without nasty surprises.

2) What template strategy should I choose: plasmid DNA or PCR/linear templates?
Both have merits. Plasmid-based templates are tried-and-true for large-scale IVT (fewer enzymatic steps post-template), they can simplify regulatory traceability and often suit later-stage GMP production. PCR-derived or enzymatically synthesised linear templates dramatically reduce pDNA dependency and can accelerate early discovery runs, plus they sidestep plasmid-related bottlenecks. A sophisticated RNA CDMO will advise hybrid models: PCR for discovery/lead optimisation and plasmid for clinical/GMP, while providing quantitative comparability data (identity, integrity, impurity profile, expression kinetics) to support the chosen path.

3) How do you minimise double-stranded RNA (dsRNA) and other IVT impurities?
Minimising dsRNA is a multi-layered exercise. Upstream, tune IVT conditions—polymerase choice, NTP ratios, magnesium and salt, temperature, and reaction time—to reduce off-target duplex formation. Co-transcriptional strategies (cap analogues, modified nucleotides) help, too. Downstream, apply orthogonal purification: cellulose-based dsRNA removal, reversed-phase and ion-exchange chromatography, HPLC polishing, and selective nucleases where applicable. Final analytics (ELISA with dsRNA-specific antibodies, dot-blot, chromatography, CGE) confirm clearance. The goal: functional RNA with minimal innate-immune triggers while keeping yields sane.

4) Which capping approaches are best and what do they practically change?
Two principal routes exist: co-transcriptional capping with cap analogues and enzymatic post-transcriptional capping. Co-transcriptional caps (CleanCap-style analogues generically) can be efficient and scale-friendly, often delivering high Cap1 fractions with fewer steps. Enzymatic capping can yield very high Cap1 specificity but adds complexity and cost. Choice depends on your modality—saRNA, circRNA, or conventional mRNA—target potency, dsRNA tolerance and manufacturability. A capable RNA CDMO will show cap-ratio analytics (LC–MS or enzymatic assays) and match cap strategy to clinical and CMC goals.

5) How do you characterise RNA quality—what analytics matter most?
Quality is a constellation, not a single star. Sound RNA characterisation includes: integrity and fragment analysis (CGE, fragment analyser), capping ratio and identity (LC–MS or enzymatic assays), dsRNA quantification (ELISA, dot-blot, orthogonal chromatography), sequence confirmation (NGS or targeted Sanger where apt), potency (in-vitro expression or functional assays), residual-template/pDNA (qPCR), residual enzymes and proteins (LC–MS/HCP ELISA), and process-related impurities (free NTPs, salts, solvents). A robust RNA CDMO validates these methods and ties release criteria to biological performance rather than cosmetic numbers.

6) What are the usual LNP engineering levers and how do they scale?
LNP performance pivots on ionisable lipid pKa, helper lipid composition, cholesterol content, PEG-lipid identity and N:P ratio, plus process variables like microfluidic mixing speed and total flow rate. At bench, microfluidic mixers control particle size and encapsulation efficiency; to scale, the vendor must preserve those hydrodynamic conditions (or use engineered continuous platforms) so particle PDI, encapsulation and potency are retained. A seasoned RNA CDMO will map the process-parameter envelope and provide engineering comparability (particle size, encapsulation, in vitro transfection) across scales, not just batch size.

7) Can you formulate RNA for ambient, refrigerated and frozen logistics? What are the trade-offs?
Yes, and each route has different engineering demands. Frozen liquid maximises shelf-life and simplifies formulation but burdens cold-chain. Refrigerated liquid eases shipping but shortens shelf-life. Lyophilised or ambient-stable formulations unlock low-resource distribution but require deep DoE work: excipient selection, Tg’/Tc mapping, cake morphology, residual moisture limits and reconstitution kinetics. The trade-offs are cost, logistics complexity and potential potency shifts. A pragmatic RNA CDMO links formulation choice to your commercial distribution network and runs stability across ICH climatic zones to de-risk launch.

8) What does a proper GMP tech transfer and comparability package look like?
A high-value tech-transfer package contains the full process narrative: engineering run data, parametrised DoE results, kLa/mixing/heat-transfer rationales, critical process parameters (CPPs), critical quality attributes (CQAs) with acceptance criteria, validated analytics, master batch records, validated cleaning, risk assessments, and comparability studies showing pre- and post-transfer equivalence. It also includes training logs, equipment qualification sheets, PQ/IOQ protocols and a rollback plan. Good transfers are proactive: they anticipate scale-up physics, single-use extractables, and supplier qualifications so the receiving site can replicate quality without re-inventing the process.

9) How do you manage supply-chain risk for critical raw materials (pDNA, NTPs, ionisable lipids, enzymes)?
You establish diversity, traceability and contingency. Dual suppliers for NTPs and enzymes, reserved allocation agreements for ionisable lipids, in-house or partnered pDNA lanes and strategic stockholding for critical reagents all help. An advanced RNA CDMO runs incoming-material quality programmes (CoA reconciliation, orthogonal testing), audits key vendors, and models lead times and consumption to create buffer strategies without bloating inventory. For clinical and commercial programs, the CDMO will include supplier data in the CMC dossier and provide documented change-control pathways for any raw-material substitutions.

10) Which regulatory paths and documentation should I expect from an RNA CDMO?
Expect phase-appropriate quality. For early work: RUO or GMP-source documentation, rapid release analytics and exploratory stability. For clinical supply: validated methods, full batch records, stability datasets, process validation, and IND/CTA/IMPD-ready CMC sections. Commercial supply demands scale validation, supplier qualifications, comparability, and post-market pharmacovigilance provisions. A mature RNA CDMO will assist with CMC writing, gap analysis vs regional guidance, and pre-submission interactions—anticipating regulator questions on dsRNA, cap structure, excipients or novel lipids. They’ll also supply audit-ready documentation packages so health authorities can follow the scientific story easily.

Closing synthesis — why Elise Biopharma is the RNA CDMO to call

Across discovery, IVT, LNP formulation, analytical depth, regulatory readiness, and manufacturing scale, choosing an RNA CDMO is about the combination of scientific depth and operational reliability. Elise Biopharma delivers an integrated platform that reduces handoffs, provides robust analytics, and translates clever sequences into reliable, manufacturable products. With teams in Cambridge, Massachusetts and Montréal, Canada, Elise couples the speed and inventiveness of a research hub with the structured, reproducible environment of GMP manufacturing.

More specifically, sponsors benefit from:

• Integrated accountability — a single partner owning sequence-to-vial performance;
• Analytical leadership — assays and validation built around functional performance rather than vanity metrics;
• Formulation fluency — options for cryo, refrigerated, and ambient-ready formats aligned to logistics;
• Manufacturing flexibility — batch and continuous routes chosen for the programme, not for vendor preference;
• Regulatory and documentation support — method validation packages and CMC expertise suitable for IND/CTA filings.

If your programme requires an RNA CDMO partner that understands both the chemistry of IVT and the physics of particle formation, and if you value transparent metrics, defensible release criteria, and white-label discretion, Elise Biopharma is set up to be that partner. Reach out for a technical intake — we’ll map your sequence to an execution plan that balances speed, reproducibility, and regulatory readiness.

Next steps

Contact our team at info@elisebiopharma.com

Learn more about our–> saRNA and circRNA Manufacturing

More of our –> circRNA & saRNA Analytical Development Services

More of –> The Top 12 Things Every Great Phage CDMO Should Do